These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28317643)

  • 1. Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap.
    Frisoni GB; Perani D; Bastianello S; Bernardi G; Porteri C; Boccardi M; Cappa SF; Trabucchi M; Padovani A
    Neurobiol Aging; 2017 Apr; 52():119-131. PubMed ID: 28317643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease.
    Lista S; Emanuele E
    Biomark Med; 2011 Aug; 5(4):411-3. PubMed ID: 21861661
    [No Abstract]   [Full Text] [Related]  

  • 3. Alzheimer's disease biomarker development: a call to funding bodies.
    Frisoni GB; Jack CR; Winblad B
    Neurobiol Aging; 2017 Apr; 52():117-118. PubMed ID: 28317642
    [No Abstract]   [Full Text] [Related]  

  • 4. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New diagnostic criteria for Alzheimer's disease.
    Zetterberg H
    Biomark Med; 2011 Aug; 5(4):407-9. PubMed ID: 21861660
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for Alzheimer's disease.
    Pauwels EK; Volterrani D; Mariani G
    Drug News Perspect; 2009 Apr; 22(3):151-60. PubMed ID: 19440558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
    Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
    J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
    Blennow K; Zetterberg H
    Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
    Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
    Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
    Marksteiner J; Hinterhuber H; Humpel C
    Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging.
    Cavedo E; Frisoni GB
    Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):237-49. PubMed ID: 21532538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
    Parnetti L; Chiasserini D
    Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away.
    Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612
    [No Abstract]   [Full Text] [Related]  

  • 20. The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie.
    Sancesario GM; Toniolo S; Chiasserini D; Di Santo SG; Zegeer J; Bernardi G; ; Musicco M; ; Caltagirone C; Parnetti L; Bernardini S
    J Alzheimers Dis; 2017; 55(4):1659-1666. PubMed ID: 27911328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.